SunTrust Robinson Humphrey downgraded Merck (NYSE: MRK) from Buy to Hold with a price target of $54.00 (from $73.00).

Analyst John Boris adjusts his model to account for Keytruda application withdraw and rising competition for Merck.

For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.

Shares of Merck closed at $58.24 Friday.

Analyst Comments Analyst PT Change Downgrades

Jefferies Upgrades Merck (MRK) to HoldOctober 31, 2017 3:51 AM Merck (MRK) PT Lowered to $67 at UBS on 'Keynote-189 Delay As Feared'October 30, 2017 10:45 AM Merck (MRK) PT Lowered to $64 at BernsteinOctober 30, 2017 8:09 AM Merck (MRK) PT Lowered to $69 at Leerink PartnersOctober 30, 2017 7:49 AM Morgan Stanley Downgrades Merck (MRK) to EqualweightOctober 30, 2017 2:11 AM Barclays Downgrades Merck (MRK) to EqualweightOctober 30, 2017 2:05 AM Merck (MRK) Withdraws European Application for KEYTRUDA in Combination with Pemetrexed and Carboplatin for First-Line Treatment of NSCLCOctober 27, 2017 4:18 PM